GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pet Pharm Biotech Co Ltd (ROCO:7762) » Definitions » Liabilities-to-Assets

Pet Pharm Biotech Co (ROCO:7762) Liabilities-to-Assets : 0.26 (As of Jun. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Pet Pharm Biotech Co Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Pet Pharm Biotech Co's Total Liabilities for the quarter that ended in Jun. 2024 was NT$174.9 Mil. Pet Pharm Biotech Co's Total Assets for the quarter that ended in Jun. 2024 was NT$662.2 Mil. Therefore, Pet Pharm Biotech Co's Liabilities-to-Assets Ratio for the quarter that ended in Jun. 2024 was 0.26.


Pet Pharm Biotech Co Liabilities-to-Assets Historical Data

The historical data trend for Pet Pharm Biotech Co's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pet Pharm Biotech Co Liabilities-to-Assets Chart

Pet Pharm Biotech Co Annual Data
Trend Dec22 Dec23
Liabilities-to-Assets
0.30 0.15

Pet Pharm Biotech Co Semi-Annual Data
Dec22 Jun23 Dec23 Jun24
Liabilities-to-Assets 0.30 - 0.15 0.26

Competitive Comparison of Pet Pharm Biotech Co's Liabilities-to-Assets

For the Drug Manufacturers - General subindustry, Pet Pharm Biotech Co's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pet Pharm Biotech Co's Liabilities-to-Assets Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pet Pharm Biotech Co's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Pet Pharm Biotech Co's Liabilities-to-Assets falls into.



Pet Pharm Biotech Co Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Pet Pharm Biotech Co's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Liabilities-to-Assets (A: Dec. 2023 )=Total Liabilities/Total Assets
=73.939/487.577
=0.15

Pet Pharm Biotech Co's Liabilities-to-Assets Ratio for the quarter that ended in Jun. 2024 is calculated as

Liabilities-to-Assets (Q: Jun. 2024 )=Total Liabilities/Total Assets
=174.859/662.22
=0.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pet Pharm Biotech Co  (ROCO:7762) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


Pet Pharm Biotech Co Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of Pet Pharm Biotech Co's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Pet Pharm Biotech Co Business Description

Traded in Other Exchanges
N/A
Address
143, Hougang 1st Road, 1-2F., No. 141, Xinzhuang District, New Taipei City, TWN, 242051
Pet Pharm Biotech Co Ltd is a Pharmaceutical company. The company is engaged in manufacturing medicinal products and medicine drugs. The products offered by the company include FDG Fluodeoxyglucose Injection (18F-FDG), Naolixi Injection (18F-FBB), Sodium fluoride injection (18F-NaF), and others.

Pet Pharm Biotech Co Headlines

No Headlines